Araris Biotech ^Company

Araris Biotech is a biotechnology start-up company that specializes in developing next-generation ADC-based safe and potent drugs for various diseases and ailments. They have developed a proprietary antibody-drug conjugate (ADC)-linker technology that enables the development of highly homogenous, stable and potent ADC therapies in a cost and time efficient manner. Their technology platform allows for the production of high-quality ADCs that do not require any engineering for site-specific conjugation, resulting in a rapid production process and quick quality control and analysis. The company was founded in 2019 and is headquartered in Zurich. They have raised a total of $43.45M in their latest funding round, Series A - III.